Bis-acridone chemotherapeutic derivatives
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsChristopher J. Michejda, Wieslaw M. Cholody, Lidia Hernandez
Life of this patent
Estimating the term…
Abstract
The present invention provides an anticancer compound having the structure: ##STR1## wherein R is --H, --CH.sub.3, or --C.sub.2 H.sub.5 ; R1 and R2 are independently --H, --OH, --NH.sub.2, --OCH.sub.3, --C(CH.sub.3).sub.3, or a halogen atom; n is 2 to 6; X and X' are independently --N or --NO.sub.2 ; Y and Y' are independently --N, --CH, or --H; and the double-slash represents a double bond or no bond; such that when X or X' is --N, Y or Y' is --CH or --N, and the double-slash is a double bond, and when X or X' is --NO.sub.2, Y or Y' is --H, and the double-slash is no bond. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier.
Claims28
A compound having the structure:
- ##STR4## wherein R is --H, --CH.sub.3, or --C.sub.2 H.sub.5 ;
- R1 and R2 are independently --H, --OH, --NH.sub.2, --OCH.sub.3, --C(CH.sub.3).sub.3, or a halogen atom;
- n is 2 to 6;
- X and X' are independently --N or --NO.sub.2 ;
- Y and Y' are independently --N, --CH, or --H;
- and the double-slash represents a double bond or no bond;
- such that when X or X' is --N, Y or Y' is --CH or --N, and the double-slash is a double bond, and when X or X' is --NO.sub.2, Y or Y' is --H, and the double-slash is no bond.
Dependencies are inferred from the claim text.